CD Biosynsis offers a premier, integrated platform for Synechococcus spp. Genome Editing and Metabolic Engineering Solutions, specifically designed to harness the photosynthetic power of these rapid-growing cyanobacteria. As a vital model for marine and freshwater microbiology, Synechococcus species (such as S. elongatus PCC 7942 and S. sp. PCC 7002) are leading "chassis" for solar-driven biomanufacturing. Our solutions address the inherent challenges of cyanobacterial engineering, including polyploidy and the requirement for efficient chromosomal segregation. By integrating CRISPR-based precision tools with systems biology, we enable the transformation of Synechococcus into high-efficiency cell factories for the production of biofuels, bioplastics, and specialty chemicals.
Our expert team provides end-to-end support for your research and industrial goals. We utilize codon-optimized Cas9 and Cas12a systems to achieve rapid homozygosity, bypassing the lengthy subculturing cycles traditionally required for cyanobacteria. From metabolic flux analysis to the final screening of high-performance lead clones, our workflow ensures that every genetic modification is stable, verified, and industrially relevant. Whether you are aiming to optimize the Carbon Concentrating Mechanism (CCM) or engineer a new biosynthetic pathway, our platform delivers the genetic precision needed to maximize your bioproduct titers.
Get a QuoteMetabolic engineering in Synechococcus requires a sophisticated understanding of the interplay between the light-harvesting apparatus and central carbon metabolism. Our solutions utilize Flux Balance Analysis (FBA) to predict the impact of genetic modifications on growth and productivity. By targeting specific enzymatic nodes, we can redirect carbon away from native storage products like glycogen toward target metabolites with high industrial value.
A major breakthrough in our platform is the use of CRISPR-mediated selective pressure to drive "accelerated segregation." Because Synechococcus contains multiple copies of its genome, traditional homologous recombination is slow. Our platform uses nucleases to actively eliminate wild-type alleles, ensuring that the engineered traits are fixed across all chromosomal copies within just a few passages. This allows for the rapid construction of complex multi-gene mutants and the optimization of pathways for the production of chemicals like isobutanol, squalene, and biodegradable polymers.
Optimized CRISPR-Cas9 and Cas12a platforms specifically tailored to minimize nuclease toxicity in cyanobacteria while ensuring high efficiency.
Biallelic disruption of target genes and accelerated segregation to reach homozygous status rapidly in polyploid strains.
Site-specific integration of pathways into validated "Neutral Sites" (NS) for stable expression without growth defects.
Tunable transcriptional silencing for studying essential genes and balancing branched metabolic networks without lethality.
Precise single-nucleotide conversion for targeted protein engineering and "scarless" point mutations in the genome.
Coordinated multi-gene engineering to maximize metabolic flux and carbon redirection toward target metabolites.
Simultaneous disruption of redundant gene families or competitive pathways to create a streamlined photosynthetic chassis.
High-throughput screening and isolation of lead variants optimized for industrial photobioreactor performance.
Quantitative phenotypic assays integrated with predictive genome-scale metabolic modeling (GEM).
Our systematic pipeline ensures high-precision engineering and data-driven selection of industrial lead strains.
1. Computational Design
2. Build & Transformation
3. HTS & Segregation
4. Stability & Verification
Establishing target metabolic models and designing codon-optimized cassettes. Designing gRNAs with minimal off-target potential for the Synechococcus genome.
Assembly of CRISPR vectors and donor templates. Transformation via natural competence (PCC 7942), conjugation (PCC 7002), or electroporation.
Verification: Genotype confirmation via Sanger or NGS sequencing. Phenotypic Analysis: Verification of growth kinetics and bioproduct yield via GC-MS/HPLC. Delivery of cryopreserved homozygous strains.
Accelerated Homozygosity
Active CRISPR selective pressure cuts the time for chromosomal segregation in polyploid Synechococcus by up to 70%.
Neutral Site Expertise
Proven integration at validated Neutral Sites (NS1, NS2, NS3) ensures stable pathway expression without growth defects.
Markerless Flexibility
Advanced scarless editing techniques enable the construction of complex, marker-free production strains for sustainable bioprocesses.
Industrial Stability
Verification of long-term genetic stability under various light and nutrient regimes ensures industrial reliability and consistency.
1. How do you ensure all genome copies are edited in Synechococcus?
We utilize CRISPR nucleases to actively kill wild-type genome copies, forcing the cell to maintain only the edited alleles. This achieves homozygosity much faster than traditional methods.
2. Which Synechococcus strains are compatible with your platform?
We have established protocols for S. elongatus PCC 7942 and S. sp. PCC 7002, and can adapt these for other marine or industrial isolates.
3. Is Cas9 toxic to cyanobacterial cells?
Constitutive expression can be toxic. We mitigate this by using inducible promoters to control expression or by utilizing Cas12a, which is often better tolerated by cyanobacteria.
4. What are Neutral Sites (NS)?
Neutral sites are genomic locations where integration doesn't disrupt native functions. This ensures stable expression and prevents the metabolic instability often seen with random integration.
5. Do you provide codon optimization for exogenous pathways?
Absolutely. We provide comprehensive codon optimization using cyanobacterial-specific matrices to ensure high translational throughput and avoid gene silencing.
6. What is the typical turnaround time for an optimized strain?
A standard project from design to homozygous strain delivery typically takes 12 to 18 weeks depending on the complexity of the pathways.
7. Is it possible to generate marker-free modified strains?
Yes. By utilizing scarless editing or curable vectors, we can provide modified strains that are free of permanent antibiotic resistance markers.
8. What type of reporting is provided?
We provide a complete technical report including NGS sequencing results, growth curves, and metabolic yield data (e.g., GC-MS/HPLC analysis).
Would you like me to discuss how our modeling services can identify the best enzymatic targets to maximize bioproduct yields in your Synechococcus strains?
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.